A Phase 2 interventional study of BPS804 in Osteogenesis Imperfecta, sponsored by Ultragenyx Pharmaceutical Inc. Completed at 6 sites in 4 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-05-11.
Sponsored by Ultragenyx Pharmaceutical Inc · Phase 2, Interventional, and Treatment
This is a randomized, open label intra-patient dose escalation study to evaluate safety and tolerability, pharmacokinetics, and pharmacodynamics of BPS804 in adults with osteogenesis imperfecta (OI).
Pharmacodynamic effect will be determined by serological biomarkers and radiologic assessments. In addition, tolerability and pharmacokinetics (PK) will be evaluated.
This study was previously posted by Mereo BioPharma and was transferred to Ultragenyx in February 2021.
85 studies on the registry are indexed under Osteogenesis Imperfecta; 20 are open to participants now.
This study's enrollment of 10 is below the median of 26 across 59 interventional studies indexed under Osteogenesis Imperfecta.
Browse Osteogenesis Imperfecta studies →Ultragenyx Pharmaceutical Inc is the lead sponsor of 63 studies on the registry; 8 are open to participants now.
Of its 13 completed or terminated interventional studies of FDA-regulated products, 11 (85%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply
Drug: BPS804
Safety and tolerability (composite outcome: standard laboratory, (serious) adverse events)
The assessment of safety will be based on primarily on the frequency of adverse events, laboratory abnormalities, and serious adverse events suspected by the investigators to be related to study treatments. The AE collection period extends from the time of first study drug administration drug until study completion. The intensity of each AE will be characterized and classified into 1 of the 3 generic categories (mild, moderate, or severe). The number and percentage of patients with adverse events will be tabulated by treatment group, body system and preferred term. The periods for adverse event tabulation will be from dose administration up to next dose administration if a further dose is given, and from dose administration to EOS for the last dose administration of a patient.
Time frame: Day 1 through 141
Determination of pharmacodynamic effect by means of biomarkers
Biomarker data from serum bone formation biomarkers: procollagen type I N-terminal propeptide, procollagen type I C-terminal propeptide, osteocalcin, and bone-specific alkaline phosphatase, and from serum bone resporption mbiomarkers: C-telopeptides of type I collagen cross-links, and N-telopeptides of type I collagen cross-links will be reported as concentration results, measured using a specific assay with a working range defined by the Lower limit of quantification and Upper limit of quantification. It will be considered a sign for efficacy, if any of the above show significant (2-sided, alpha=0.05) increase versus baseline in the BPS804 group on day 43.
Time frame: Day 1 and Day 43
Change in Z-score from baseline to Day 141
Bone mineral density will be assessed by dual-energy X-ray absorptiometry of the lumbar spine. Analysis will include four vertebral levels from L1 to L4. Individual vertebral levels may be excluded due to artifact. Bone mineral density Z-scores will be used as these are a comparison of a patient's BMD to that of a patient of the same age, sex, and ethnicity. The comparison of change from baseline with the matching change in the reference group will be done by 2-sample t-tests (1-sided). It will be considered a sign for efficacy, if any of the above show significant (2-sided, alpha=0.05) increase versus baseline in the BPS804 group on day 141.
Time frame: Day 1 and Day 141
Determination of the serum concentration-time profiles of BPS804
Individual and overlaying individual serum concentration-time profiles of BPS804 will be constructed from the serial sampling on Day 1 (prior to administration and 3x after administration) and Days 2, 8, 15 (2x), 16, 29 (4x), 30, 36, 43, 57, 85, 113,141. In addition arithmetic and geometric mean serum concentration-time profiles of BPS804 will be constructed from the above data points.
Time frame: Day 1 (prior to administration and 3x after administration) and Days 2, 8, 15 (2x), 16, 29 (4x), 30, 36, 43, 57, 85, 113,141
Determination of the area under the serum concentration-time curve from time zero to the end of the dosing interval tau after the first dose
The area under the serum concentration-time curve from time zero to the end of the dosing interval tau after the first dose will be derived using using non-compartmental methods from data collected on Day 1 (4x) and Days 2, and 8.
Time frame: Day 1 (prior to administration and 3x after administration) and Days 2, and 8
Determination of the maximal concentration after the first dose
The maximal concentration after the first dose will be derived using using non-compartmental methods from data collected Day 1 (4x) and Days 2, and 8.
Time frame: Day 1 (prior to administration and 3x after administration) and Days 2, and 8
Determination of the time of maximal concentration after the first dose
The time of maximal concentration after the first dose will be derived using using non-compartmental methods from data collected Day 1 (4x) and Days 2, and 8.
Time frame: Day 1 (prior to administration and 3x after administration) and Days 2, and 8
Determination of the maximal concentration after the second dose
The maximal concentration after the second dose will be derived using using non-compartmental methods from data collected from days 15 (2x) and 16.
Time frame: Day 15 (prior to administration and 1x after administration) and Day 16
Determination of the time of maximal concentration after the second dose
The time of maximal concentration after the second dose will be derived using using non-compartmental methods from data collected from days 15 (2x) and 16.
Time frame: Day 15 (prior to administration and 1x after administration) and Day 16
Determination of the area under the serum concentration-time curve from time zero to infinity after the third dose
The area under the serum concentration-time curve from time zero to the end of the dosing interval tau after the third dose will be derived using non-compartmental methods from data collected on Days 29 (4x), 30, 36, 43, 57, 85, 113, and 141.
Time frame: Days 29 (prior to administration and 3x after administration) and 30, 36, 43, 57, 85, 113, and 141
Determination of the area under the serum concentration-time curve from time zero to the time of the last quantifiable concentration after the third dose
The area under the serum concentration-time curve from time zero to the time of the last quantifiable concentration after the third dose will be derived using non-compartmental methods from data collected on Days 29 (4x), 30, 36, 43, 57, 85, 113, and 141.
Time frame: Days 29 (prior to administration and 3x after administration) and 30, 36, 43, 57, 85, 113, and 141
Determination of the area under the serum concentration-time curve from time zero to the end of the dosing interval tau after the third dose
The area under the serum concentration-time curve from time zero to the end of the dosing interval tau after the third dose will be derived using non-compartmental methods from data collected on Days 29 (4x), 30, 36, 43, 57, 85, 113, and 141.
Time frame: Days 29 (prior to administration and 3x after administration) and 30, 36, 43, 57, 85, 113, and 141
Determination of the maximal serum concentration after the third dose
The maximal serum concentration after the third dose will be derived using using non-compartmental methods from data collected on Days 29 (4x), 30, 36, 43, 57, 85, 113, and 141.
Time frame: Days 29 (prior to administration and 3x after administration) and 30, 36, 43, 57, 85, 113, and 141
Determination of the time of maximal concentration after the third dose
The time of maximal concentration after the third dose will be derived using using non-compartmental methods from data collected on Days 29 (4x), 30, 36, 43, 57, 85, 113, and 141.
Time frame: Days 29 (prior to administration and 3x after administration) and 30, 36, 43, 57, 85, 113, and 141
Determination of the terminal elimination half-life after the third dose
The terminal elimination half-life after the third dose will be derived from data collected on Days 29 (4x), 30, 36, 43, 57, 85, 113, and 141 using a compound-specific modeling approach.
Time frame: Days 29 (prior to administration and 3x after administration) and 30, 36, 43, 57, 85, 113, and 141
Determination of the concentration of total sclerostin in serum
The function of sclerostin is described as an endogenous negative regulator of bone formation. Total serum sclerostin will be measured from samples collected at screening and on days 1, 8, 15, 29, 36, 43, 57, 85, 113, and 141
Time frame: Screening, Days 1, 8, 15, 29, 36, 43, 57, 85, 113, 141
Immunogenicity evaluation in serum
Immunogenicity will only be assessed in patients randomized to the treatment group. Anti-BPS804 antibodies will be measured in human serum on Days 1, 29, 85, and 141 An immunogenicity positive patient at end of study will be followed up until anti-BPS804 antibody levels are back to levels measured on Day 1.
Time frame: Days 1, 29, 85, and 141
This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ultragenyx Pharmaceutical Inc